Miniatura

Fitxers

12474_9295622_pre-proof_-_impact_of_sars-cov-2_pandemic_on_vascular_liver_deseases.pdf (1.23 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2021-12-26

Llicència de publicació

cc by-nc-nd (c) AGA Institute, 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/182343

Impact of SARS-CoV-2 pandemic on vascular liver diseases

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.cgh.2021.12.032

Resum

Vascular liver diseases (VLD) are represented mainly by portosinusoidal vascular disease (PSVD), non-cirrhotic splanchnic vein thrombosis (SVT) and Budd Chiari syndrome (BCS). It is unknown whether patients with VLD constitute a high-risk population for complications and greater COVID-19-related mortality from SARS-CoV-2 infection. Our objective was to assess the prevalence and severity of SARS-CoV-2 infection among patients with VLD, as well as to assess its impact on hepatic decompensation and survival.This is a observational international study analyzing the prevalence and severity of SARS-CoV-2 infection in VLD between March 2020-March 2021 comparing with the general population (GP). Patients from Spain (5 centers, n = 493) and France (1 center, n = 475) were included.Nine hundred and sixty-eight patients were included: 274 PSVD, 539 SVT and 155 BCS. Among them, 138 (14%) were infected with SARS-CoV-2: 53 PSVD, 77 SVT and 8 BCS. The prevalence of SARS-CoV-2 infection in PSVD (19%) and SVT (14%) was significantly higher than in GP (6.5%, p < 0.05), while it was very similar in BCS (5%). In terms of infection severity, patients with VLD also presented a higher need of hospital admission (14% vs 7.3%, p<0.01), ICU admission (2% vs 0.7%, p< 0.01) and mortality (4% vs 1.5%, p < 0.05) than GP. Previous history of ascites (50% vs 8%, p < 0.05) and post-COVID-19 hepatic decompensation (50% vs 4%, p < 0.05) were associated to COVID-19 mortality.PSVD and SVT patients could be at higher risk of infection by SARS-CoV-2 and at higher risk of severe COVID-19 disease.Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Matèries

SARS-CoV-2, COVID-19, Malalties vasculars, Malalties del fetge

Matèries (anglès)

SARS-CoV-2, COVID-19, Vascular diseases, Liver diseases

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

BAIGES AZNAR, Anna, CERDA, Eira, AMICONE, Caroline, TELLEZ, Luis, ALVARADO TAPIAS, Edilmar, PUENTE, Angela, FORTEA, Jose ignacio, LLOP, Elba, ROCHA, Filipa, ORTS, Lara, ROS FARGAS, Olivia, VIZCARRA, Pamela, ZEKRINI, Kamal, AMARA LOUNES, Ould, TOUATI, Ghiles, JIMENEZ, Natalia, SERRANO, Maria jose, FALGÀ, Àngels, MAGAZ MARTÍNEZ, Marta, OLIVAS, Pol, BETANCOURT, Fabian, PÉREZ CAMPUZANO, Valeria, TURON, Fanny, PAYANCÉ, Audrey, GORIA, Odile, RAUTOU, Pierre-emmanuel, HERNÁNDEZ GEA, Virginia, VILLANUEVA, Càndid, ALBILLOS, Agustín, PLESSIER, Aurélie, GARCÍA PAGÁN, Juan carlos. Impact of SARS-CoV-2 pandemic on vascular liver diseases. _Clinical Gastroenterology And Hepatology_. 2021. [consulta: 12 de febrer de 2026]. [Disponible a: https://hdl.handle.net/2445/182343]

Exportar metadades

JSON - METS

Compartir registre